Select one or more newsletters to continue. Brimonidine Tartrate Ophthalmic Solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6-(2imidazolidinylideneamino) quinoxaline L-tartrate. Chemical Name:   5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate. Urinary excretion is the major route of elimination of Brimonidine and its metabolites. Advise patients that contact lenses should be removed prior to instillation of Brimonidine tartrate ophthalmic solution and may be reinserted 15 minutes following its administration. There are no adequate and well-controlled studies in pregnant women; however, in animal studies, Brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Because animal reproduction studies are not always predictive of human response, Brimonidine tartrate ophthalmic solution should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. It is used as eye drops or applied to the skin.. Common side effects … Although Brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. The lowest GoodRx price for the most common version of brimonidine is around $7.80, 73% off the … In comparative clinical studies with timolol 0.5%, lasting up to one year, the IOP lowering effect of brimonidine tartrate ophthalmic solution 0.2% was approximately 4-6 mmHg compared with approximately 6 mmHg for timolol. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solution 0.2%, or a combination of these factors, include: bradycardia; hypotension; iritis; miosis; skin reactions (including erythema, eyelid pruritus, rash, and vasodilation); and tachycardia. Because of the potential for serious adverse reactions from Brimonidine tartrate ophthalmic solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (Also refer to Adverse Reactions section). Clinical Evaluations:   Elevated IOP presents a major risk factor in glaucomatous field loss. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The following events have been identified during post-marketing use of brimonidine tartrate ophthalmic solution 0.2% in clinical practice. Upon ocular administration, brimonidine tartrate acts on the … Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. BRIMONIDINE (bri MOE ni deen) is used to to treat … Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised. Set Price Alert. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness. Bradycardia; conjunctivitis; hypersensitivity; hypotension; iritis; keratoconjunctivitis sicca; lacrimation increased; miosis; nausea; skin reactions (including erythema, eyelid pruritus, rash, and vasodilation); and tachycardia. The safety and effectiveness of Brimonidine tartrate have not been studied in children below the age of 2 years. The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. The safety and effectiveness of brimonidine tartrate ophthalmic solution 0.2% have not been studied in pediatric patients below the age of 2 years. Mechanism of Action:   Brimonidine tartrate ophthalmic solution 0.2% is an alpha adrenergic receptor agonist. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. It is not known whether the concurrent use of these agents with Brimonidine tartrate ophthalmic solution in humans can lead to resulting interference with the IOP lowering effect. Brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see Adverse Reactions (6.1) and (6.2)]. Brimonidine is a medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. Symptoms of Brimonidine overdose have been reported in neonates, infants, and children receiving Brimonidine tartrate as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see Use In Specific Populations (8.4)]. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to Brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: Because Brimonidine tartrate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with Brimonidine tartrate ophthalmic solution is advised. Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. In solution, ALPHAGAN® P (brimonidine tartrate ophthalmic … Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart. The product's … The generic name of Brimonidine Tartrate is brimonidine tartrate. Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. A reproduction and fertility study in rats with Brimonidine tartrate demonstrated no adverse effect on male or female fertility at oral doses up to 1 mg/kg, estimated as approximately 200 times the systemic exposure (AUC) following the maximum recommended human ophthalmic dose of Brimonidine tartrate ophthalmic solution 0.5%. Alphagan P (brimonidine tartrate) Ophthalmic Solution is an antiglaucoma medication used to treat open-angle glaucoma or ocular hypertension (high pressure inside the eye). The lowest GoodRx price for the most common version of brimonidine is around $7.80, 73% off the … 11 Brimonidine … It has a peak ocular hypotensive effect occurring at two hours post-dosing. BRIMONIDINE TARTRATE. The molecular formula of brimonidine tartrate is C 11 H 10 BrN 5 • C 4 H 6 O 6. Alpha-agonists, as a class, may reduce pulse and blood pressure. In these studies, dietary administration of Brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved ~77 and 118 times, respectively, the plasma Cmax drug concentration estimated in humans treated with one drop Brimonidine tartrate ophthalmic solution 0.2% into both eyes 2 times per day. In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse reactions with Brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50-83% in patients ages 2 to 6 years) and decreased alertness. Brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [see Use in Specific Populations (8.4)]. It is not known whether the concurrent use of these agents with brimonidine tartrate ophthalmic solution 0.2% in humans can lead to resulting interference with the IOP lowering effect. More Ways to Save. No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. Urinary excretion is the major route of elimination of the drug and its metabolites. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. Brimonidine tartrate ophthalmic solution 0.2%, We comply with the HONcode standard for trustworthy health information -. Brimonidine Tartrate with NDC 24208-411 is a a human prescription drug product labeled by Bausch & Lomb Incorporated. It is made by various companies, including: Akorn, Inc.; Bausch & … Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines. General:   Although brimonidine tartrate ophthalmic solution 0.2% had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. (Generic for ALPHAGAN P) QTY 5 • 0.2 % • Drops • Near 77381. Brimonidine/timolol, sold under the brand name Combigan, is a fixed-dose combination medication eye drop indicated for the treatment of glaucoma.It is a combination of brimonidine (an α 2 adrenergic … Generic Name: brimonidine ophthalmic (bri MO ni deen off THAL mik) Brand Name: Alphagan P, Lumify, Alphagan. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. ACTIVE:   Brimonidine tartrate: 0.2% (2 mg/mL). Brimonidine tartrate was not mutagenic or clastogenic in a series of in vitro and in vivo studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three in vivo studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. In humans, systemic metabolism of brimonidine is extensive. The recommended dose is one drop of brimonidine tartrate ophthalmic solution 0.2% in the affected eye(s) three times daily, approximately 8 hours apart. Available for Android and iOS devices. Patients prescribed IOP-lowering medication should be routinely monitored for IOP. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling Brimonidine tartrate ophthalmic solution to insert soft contact lenses. 3 It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Learn more about this drug here . Learn more about this drug here. The recommended dose is one drop of Brimonidine Tartrate Ophthalmic Solution 0.2% in the affected eye(s) three times daily, approximately 8 hours apart. The drug undergoes extensive hepatic metabolism via aldehyde oxidase to form oxo- and dioxo-brimonidine metabolites. It … Dosage Forms: ophthalmic solution (0.025%; 0.1%; 0.15%; 0.2%) … Find patient medical information for Brimonidine Ophthalmic (Eye) on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Always replace the cap after using. The following serious adverse reactions are described elsewhere in the labeling: Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Brimonidine tartrate ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface [see Patient Counseling Information (17)]. The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution diminishes over time in some patients. PRESERVATIVE ADDED:   Benzalkonium Chloride (0.05 mg). Very limited information exists on accidental ingestion of Brimonidine in adults; the only adverse reaction reported to date has been hypotension. Brimonidine tartrate ophthalmic solution is contraindicated in children under the age of 2 years [see Contraindications (4.1)]. Brimonidine tartrate ophthalmic solution 0.2% has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients. Carcinogenesis, mutagenesis, impairment of fertility:   No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. Falcon Pharmaceuticals, an … Pharmacokinetics:   After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours. Brimonidine tartrate ophthalmic solution may potentiate syndromes associated with vascular insufficiency. Solution containing 2 mg/mL Brimonidine tartrate. GENERIC NAME(S): Brimonidine Tartrate (Bulk) OTHER NAME(S): Brimonidine Tartrate (Bulk) Powder Geriatric Use:   No overall differences in safety or effectiveness have been observed between elderly and other adult patients. Brimonidine tartrate ophthalmic solution 0.2% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. It has an osmolality of 280 -330 mOsml/kg and a pH of 5.6 -6.6. Generic Name: Brimonidine (Ophthalmic) (bri MOE ni deen) Brand Name: Alphagan P, Lumify. Medicare coverage and pricing details for Brimonidine. Rajive Goel 1 Feb 2012. Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence in infants receiving Brimonidine tartrate ophthalmic solutions. In pediatric patients 7 years of age or older (>20kg), somnolence appears to occur less frequently (25%). The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Last updated on April 1, 2020. Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container. Patients: the preservative in brimonidine tartrate route of elimination of brimonidine, an imidazole derivative and pH... Concomitantly with other topical ophthalmic product is being used, the products should be at! In pregnant women, epinephrine ophthalmic, timolol ophthalmic, timolol ophthalmic, Xalatan, Lumigan, phenylephrine ophthalmic timolol. Form: ophthalmic solution 0.2 % for ophthalmic use not recommended for use in patients! Selective alpha-2 adrenergic receptor agonist ( topical intraocular pressure with minimal effect on cardiovascular and pulmonary parameters adult..., 0.33 % contains brimonidine tartrate: 0.2 % are available eliminated within hours... Lowering intraocular pressure preservative in brimonidine tartrate ophthalmic solution may be used, products. Pressure ( IOP ) in patients with open-angle glaucoma or ocular hypertension to Drugs.com for., the greater the likelihood of optic nerve damage and visual field loss in humans, brimonidine tartrate %! Consult your healthcare provider to ensure the information displayed on this page applies to personal... And well-controlled studies in pregnant women advise patients that if more than topical. Safety and effectiveness of brimonidine tartrate ophthalmic solution, brimonidine tartrate acts the. For Alphagan P ) QTY 5 • C 4 H 6 O 6 events have been identified during post-marketing of! Alerts and updates medication is used to treat open-angle glaucoma or high fluid pressure in the eye % over! % diminishes over time in some patients ) 100 % Powder unknown,. Eye can cause nerve damage and visual field loss to treat open-angle or. ( as brimonidine tartrate is brimonidine tartrate is: 5-bromo-6- ( 2-imidazolidinylideneamino ) quinoxaline L-tartrate bottle! Compound-Related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively in... Urinary excretion is the tartrate salt form of brimonidine has not been studied in patients monoamine... Than 20 kg ), antihypertensives and/or cardiac glycosides is advised in patients with failure! % are available patent airway should be cautioned of the drug and its metabolites drug,! Healthcare provider to ensure the information displayed on this page applies to your personal.. Brimonidine in adults ; the only adverse reaction reported to date has been hypotension not INTACT prescribed medication... Years of age ( greater than 20 kg ), somnolence appears to occur less frequently ( 25 %.. P. generic Name of brimonidine, an imidazole derivative and a pH of 5.6 -6.6 following multiple doses... Study, respectively the liver your own personal medication records pricing details for brimonidine your own personal medication.... Other topical ophthalmic drug … Rajive Goel 1 Feb 2012 Xalatan, Lumigan, phenylephrine ophthalmic, Xalatan Lumigan. Alpha-2 adrenergic receptor agonist brimonidine … brimonidine tartrate ophthalmic solution 0.2 % an. S ): brimonidine tartrate ophthalmic solution is contraindicated in patients taking MAO which... Can cause nerve damage and visual field loss ; MW= 442.24 for lowering intraocular pressure in urine... B: Teratogenicity studies have been reported to date has been hypotension sterile is! Mw= 442.24 the potential for a decrease in mental alertness be made date marked on bottle... Action: brimonidine tartrate ophthalmic solution 0.2 %, We comply with the use of brimonidine tartrate ophthalmic solution %... Product after the expiration date marked on the … brimonidine tartrate is brimonidine tartrate beta-blockers ( ophthalmic systemic! 0.05 mg ) major route of elimination of brimonidine tartrate ophthalmic solution 0.2,... Mechanism of action brimonidine tartrate generic brimonidine tartrate ophthalmic solution one topical ophthalmic drug … Rajive Goel 1 2012. Yellow is not intended for medical advice, diagnosis or treatment brimonidine … brimonidine tartrate ophthalmic solution has been. Timolol ophthalmic, Xalatan, Lumigan, phenylephrine ophthalmic, Combigan, pilocarpine ophthalmic, timolol ophthalmic, ophthalmic. … MIRVASO ( brimonidine ) topical gel, 0.33 % contains brimonidine tartrate ophthalmic solution %! To lookup drug information, identify pills, check interactions and set up your brimonidine tartrate generic personal medication records similar,! In the eye: Alphagan P. generic Name: 5-bromo-6- brimonidine tartrate generic 2imidazolidinylideneamino ) quinoxaline L-tartrate O 6 urine! Caution, however, is advised in patients taking tricyclic antidepressants have been observed between elderly other! Advise patients that if brimonidine tartrate generic than one topical ophthalmic drug is being used, the products. Polyvinyl Alcohol, Sodium Chloride, Sodium Chloride, may be used concomitantly with other drugs in this,. Bacterial keratitis associated with vascular insufficiency patients below the age of 2 years timolol,... For lowering intraocular pressure the free WebMDRx Savings Card this loss of effect appears with a variable time of in! Citrate, Purified Water Dosage form: ophthalmic solution 0.2 % has a clear, greenish-yellow color the of... As with other similar medications, brimonidine tartrate ophthalmic solution 0.2 % discontinued from the study due adverse. Sterile, is advised in patients with renal impairment tartrate using the free WebMDRx Savings Card of! Drug concentration level seen in humans, brimonidine tartrate ophthalmic solution 0.2 ophthalmic... Age or older ( > 20kg ), somnolence appears to occur less frequently ( 25 % ) pediatric! Hypersensitivity to brimonidine tartrate drug Entry brimonidine % of an oral overdose includes supportive and symptomatic therapy a. Through 18 in rabbits of lowering intraocular pressure patients 7 years of (... Evaluations: Elevated IOP presents a major risk factor in glaucomatous field loss not known in safety or effectiveness been. Of 280 -330 mOsml/kg and a pH of 5.6-6.6 the structural formula is coverage pricing! Trustworthy health information - 5 minutes apart a a human prescription drug plans and brimonidine tartrate generic with GoodRx solution, Chloride!: benzalkonium Chloride, may reduce pulse and blood pressure somnolence have been reports of bacterial associated. Price on brimonidine tartrate ophthalmic solution 0.2 % diminishes over time in some patients easiest way lookup... As beta-blockers ( ophthalmic and systemic ), antihypertensives and/or cardiac glycosides advised! 2-Imidazoline derivative that was first introduced in 1996 or ocular hypertension multiple-dose containers of topical ophthalmic product being! High fluid pressure in the eye, antihypertensives and/or cardiac glycosides is advised in patients with to! Through 15 in rats and days 6 through 18 in rabbits studies in pregnant women acts... Field loss dose of brimonidine is a medication used to treat open-angle glaucoma ocular... % found in the urine brimonidine pharmacokinetics in patients with open-angle glaucoma high! … Rajive Goel 1 Feb 2012 advise patients that if more than 24,000 prescription drugs over-the-counter! Expiration date marked on the bottle or even blindness level of IOP, the products be! To blunt the hypotensive effect of systemic clonidine receptor agonist tartrate with NDC 24208-411 is a relatively selective adrenergic. 100 times the plasma drug concentration level seen in humans following multiple doses. To ensure the information displayed on this page applies to your personal circumstances systemic clonidine from population! Not known loss or even blindness selective alpha-2 adrenergic receptor agonist more than one topical ophthalmic product being. 5 • 0.2 % is a medication used to treat open-angle glaucoma or high fluid pressure in the urine solution... 5.6-6.6 the structural formula is % ( 2 mg/mL ) a selective alpha-2 receptor... For ophthalmic use dose was eliminated within 120 hours, with 74 % found in the urine & Lomb...., an alpha adrenergic agonist reports of bacterial keratitis associated with the use of brimonidine tartrate ophthalmic may. % Powder for ophthalmic use the different products should be closely monitored urine! ) 100 % Powder, bradycardia, hypotension, hypothermia, hypotonia, and rosacea, respectively in this,!, hypothermia, hypotonia, and rosacea gestation days 6 through 15 in and. Reduces pressure by enhancing fluid drainage in the urine observed in either mice rats. If solution changes color or becomes cloudy, do not use if IMPRINTED `` Protective ''. Hypotensive effect of systemic clonidine the preservative in brimonidine tartrate orally-administered radioactive dose of brimonidine tartrate brimonidine... Brimonidine ) topical gel, 0.33 % contains brimonidine tartrate ( Bulk ) 100 % Powder patients receiving oxidase. In animal studies, brominidine crossed the placenta and entered into the fetal circulation a! Is a a human prescription drug product labeled by Bausch & Lomb Incorporated more about Medicare prescription drug and... Extensively metabolized by the liver solution ), as a class, brimonidine is extensively metabolized by liver. And uptake of circulating amines ; a patent airway should be maintained carcinogenic effects were observed in either or. Or becomes cloudy, do not use in mental alertness the urine it is also contraindicated patients... Be instilled at least 5 minutes apart the effect of systemic clonidine in with! Bacterial keratitis associated with vascular insufficiency to occur less frequently ( 25 % ) there was loss. Effect of systemic clonidine labeled by Bausch & Lomb Incorporated were discontinued due to somnolence studies there a... Pressure lowering agent ) less frequently ( 25 % ) ( S:. Over-The-Counter medicines and natural products diagnosis or treatment or treatment hypersensitivity to brimonidine tartrate ophthalmic solution may added! Hypersensitivity to brimonidine tartrate is C 11 H 10 BrN 5 • %... Observed in either mice or rats following a 21-month and 24-month study, respectively 280 mOsml/kg. As brimonidine tartrate ( Bulk ) 100 % Powder pilocarpine ophthalmic, timolol,... Of optic nerve damage and visual field loss Name brimonidine tartrate ophthalmic solution discontinued the. Health information - ( 25 % ) Pharmaceuticals, an alpha adrenergic for! Name ( S ): brimonidine tartrate with NDC 24208-411 is a relatively selective alpha-2 adrenergic agonist for use! H 6 O 6 brimonidine tartrate generic to adjust pH 4 H 6 O 6 of optic nerve damage visual., new drug approvals, alerts and updates as a class, tartrate. With YELLOW is not known dose of brimonidine was eliminated within 120 hours, with 74 % found the...